31 Jan OpGen appoints Noel Doheny as CEO
Madison, Wis. – OpGen, Inc., a Madison-based company that provides DNA analysis for infectious disease management, has appointed Noel Doheny as its new chief executive officer.
Doheny, who has joined the OpGen Board of directors, has more than 30 years of experience in leading publicly traded and start-up healthcare and biotechnology businesses, including his most recent stint as senior vice president of molecular diagnostics for Affymetrix.
Prior to joining OpGen, Doheny held executive roles for Ciba-Corning (now Siemens), Biostar (now Inverness Medical), and Qiagen. Ron Lennox, chairman of the board of OpGen and partner at the investment firm CHL Medical Partners, cited Doheny’s ability to commercialize technology.
OpGen is commercializing a DNA analysis technology, known as optical mapping, that helps identify microorganisms. Optical mapping is used to provide comparative genomic analysis of a range of organisms of importance to human health.
In September of 2007, OpGen announced that it had raised $23.6 million in equity financing in a round led by CHL, Highland Capital Partners, and Versant Venture. Each investment organization has been involved in commercializing technologies for diagnostic and research applications.
• OpGen enters strategic investment agreement with In-Q-Tel
• OpGen’s $23.6M venture capital score could transform hospital care
• OpGen layoffs precede another funding round